AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: RXRX
Report Date: 2026-06-04
Full Report: https://amaly.io/stock/RXRX

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Recursion Pharmaceuticals (RXRX), an AI-driven biotechnology company focused on drug discovery, demonstrates strong compliance in business activities and low debt levels but faces challenges due to elevated interest income from investments, exceeding Shariah thresholds. Financial screening reveals passes on debt and liquidity ratios across major standards, but failure on non-compliant income purification requirements. No controversies or non-permissible activities identified, with positive ESG alignment. Overall, while the core business is halal, financial impurities require significant purification. Investors should monitor for improvements in income sources.

Primary Compliance Concerns:
- Interest income ratio of 24.16% exceeds 5% threshold across AAOIFI, MSCI, and S&P standards

Purification Requirement: 24.16%
Index Inclusion: Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 4.5%
Liquidity Ratio: 24.1%
Interest Income Ratio: 24.2%
Purification Required: 24.16%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-09-30

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-19T00:00:00Z

---
Full interactive report: https://amaly.io/stock/RXRX
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.